Genetic Testing for Malignant Hyperthermia in North America

Anesthesiology

Volumn 100, Issue 2, 2004, Pages 212-214

  Nelson, Thomas E ^a   Rosenberg, Henry ^b,c   Muldoon, Sheila M ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Malignant Hyperthermia Assoc U S   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANTROLENE; INHALATION ANESTHETIC AGENT;

CHROMOSOME 19; CLINICAL GENETICS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; EDITORIAL; GENETIC SCREENING; HUMAN; MALIGNANT HYPERTHERMIA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROPHYLAXIS;

ANESTHETICS, INHALATION; CAFFEINE; GENETIC SCREENING; HALOTHANE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; NORTH AMERICA; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 1642458346     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200402000-00004     Document Type: Editorial

References (28)

1. Allen GC, Larach MG, Kunselman AR: The sensitivity and specificity of the caffeine-halothane contracture test: A report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. ANESTHESIOLOGY 1998; 88:579-88
2. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wapper F: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41:955-66
3. Nelson TE: Malignant hyperthermia: A pharmacogenetic disease of Ca++ regulating proteins. Curr Mol Med 2002; 2:347-69
4. Sei Y, Sambuughin N, Muldoon S: Malignant Hyperthermia Genetic Testing in North America Working Group Meeting. ANESTHESIOLOGY 2003; 100:464-5
5. McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343:562-4
6. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559-61
7. Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, Weiler JE, O'Brien PJ, MacLennan DH: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253:448-51
8. Roberts MC, Mickelson JR, Patterson EE, Nelson TE, Armstrong PJ, Brunson DB, Hogan K: Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). ANESTHESIOLOGY 2001; 95:716-25
9. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J: Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002; 277:34918-23
10. Nelson TE, Lin M, Zapata-Sudo G, Sudo RT: Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel: Clinical implications. ANESTHESIOLOGY 1996; 84:1368-79
11. Yang T, Ta TA, Pessah IN, Allen PD: Functional defects in six RyR1 mutations associated with malignant hyperthermia and their impact on skeletal E-C coupling. J Biol Chem 2003; 278:25722-30
12. Treves S, Larini F, Menegazzi P, Steinberg TH, Koval M, Vilsen B, Andersen JP, Zorzato F: Alteration of intracellular Ca2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem J 1994; 301:661-5
13. Tong J, Oyamada H, Demaurex N, Grinstein S, McCarthy TV, MacLennan DH: Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272:26332-9
14. Rueffert H, Olthoff D, Deutrich C, Meinecke CD, Froster UG: Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: Identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46:692-8
15. Monnier N, Procaccio V, Stieglitz P, Lunardi J: Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60:1316-25
16. Brooks C, Robinson RL, Halsall PJ, Hopkins PM: No evidence of mutations in the CACNA1S gene in the UK malignant hyperthermia population. Br J Anaesth 2002; 88:587-9
17. Robinson RL, Hopkins PM: A breakthrough in the genetic diagnosis of malignant hyperthermia. Br J Anaesth 2001; 86:166-8
18. Urwyler A, Deufel T, McCarthy T, West S. European Malignant Hyperthermia Group: Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86:283-7
19. Rosenberg H, Antognini JF, Muldoon S: Testing for malignant hyperthermia. ANESTHESIOLOGY 2002; 96:232-7
20. Censier K, Urwyler A, Zorzato F, Treves S: Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals: Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. J Clin Invest 1998; 101:1233-42
21. Sei Y, Gallagher KL, Basile AS: Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem 1999; 274:5995-6002
22. Sei Y, Brandom BW, Bina S, Hosoi E, Gallagher KL, Wyre HW, Pudimat PA, Holman SJ, Venzon DJ, Daly JW, Muldoon S: Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. ANESTHESIOLOGY 2002; 97:1052-8
23. Loke JC, Kraev N, Sharma P, Du G, Patel L, Kraev A, MacLennan DH: Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. ANESTHESIOLOGY 2003; 99:297-302
24. Bendahan D, Kozak-Ribbens G, Rodet L, Confort-Gouny S, Cozzone PJ: Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: Application to diagnosis. ANESTHESIOLOGY 1998; 88:96-107
25. Anetseder M, Hager M, Muller CR, Roewer N: Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 2002; 359:1579-80
26. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson TE, Fletcher JE, Rosenberg H, Muldoon SM: North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. ANESTHESIOLOGY 2001; 95:594-9
27. Sambuughin N, McWilliams S, de Bantel A, Sivakumar K, Nelson TE: Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001; 69:204-8
28. Sambuughin N, Nelson TE, Jankovic J, Xin C, Meissner G, Mullakandov M, Ji J, Rosenberg H, Sivakumar K, Goldfarb LG: Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord 2001; 11:530-7